Cart
sales@molnova.com
Flutamide
CAS No. 13311-84-7
Flutamide( Niftolide | NSC 147834 | NSC 251876 | SCH 13521 )
Catalog No. M11320 CAS No. 13311-84-7
Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | 28 | In Stock |
|
| 500MG | 43 | In Stock |
|
| 1G | 45 | In Stock |
|
Biological Information
-
Product NameFlutamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionFlutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor.
-
DescriptionFlutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor.
-
In Vitro——
-
In Vivo——
-
SynonymsNiftolide | NSC 147834 | NSC 251876 | SCH 13521
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number13311-84-7
-
Formula Weight276.21
-
Molecular FormulaC11H11F3N2O3
-
Purity>98% (HPLC)
-
SolubilityEthanol: 55 mg/mL (199.12 mM); DMSO: 55 mg/mL (199.12 mM)
-
SMILESCC(C)C(NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)=O
-
Chemical NameN-(4-nitro-3-(trifluoromethyl)phenyl)isobutyramide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chang HC, et al. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11173-7.
molnova catalog
related products
-
UT-155
UT-155 is a selective and potent antagonist of the androgen receptor (AR) (Ki: 267 nM for UT-155 binding to AR-LBD).
-
AR antagonist 1
AR antagonist 1 is a potent antagonist of the androgen receptor. It binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266.
-
Saclofen
Saclofen is a sulfonic analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that acts as a competitive antagonist of the GABAB receptor (IC50: 7.8 μM).
